Introduction
============

The early (90‐day) risk of recurrence of stroke and other vascular events following index transient ischemic attack (TIA) and minor ischemic stroke is very high, even in patients treated with aspirin, the current standard of care.^[@b1]--[@b3]^ Treatment with the combination of clopidogrel and aspirin taken soon after a TIA or minor stroke was found to decrease the 90‐day risk of stroke (hazard ratio 0.68, 95% CI 0.57 to 0.81, *P*\<0.001) but did not increase the risk of hemorrhage compared with aspirin alone in the CHANCE stroke trial (Clopidogrel in High‐risk patients with Acute Non‐disabling Cerebrovascular Events Trial).^[@b4]^ Although the clopidogrel‐aspirin regimen is a reasonable early management for TIA and minor ischemic stroke, the extent of its adoption and use in clinical practice will depend―to some extent―on its economic practicality. However, the cost‐effectiveness, which is very important for patients, clinicians, and policy‐makers, has not been evaluated. In this analysis, we sought to determine the cost‐effectiveness of adding clopidogrel to aspirin in patients with acute TIA or minor stroke.

Methods
=======

Model Overview
--------------

We adhered to the recommendations of the Panel on Cost‐effectiveness in Health and Medicine.^[@b5]^ Markov models are generally used to estimate the long term costs and outcomes associated with a disease and a particular healthcare intervention, in which the disease is divided into distinct states and transits between these states over a discrete time period under assigned transitions probabilities.^[@b6]^ A Markov model was developed ([Figure 1](#fig01){ref-type="fig"}) to simulate the cost‐effectiveness of two antiplatelet treatment strategies for high‐risk patients with acute minor stroke or TIA: (1) clopidogrel‐aspirin strategy: a 300‐mg loading dose of clopidogrel followed by 75 mg clopidogrel per day on days 2 to 90 plus aspirin 75 to 300 mg on day 1 followed by 75 mg/day on days 2 to 21 or (2) aspirin‐alone strategy: aspirin 75 to 300 mg on day 1 followed by 75 mg/day on days 2 to 90. The base‐case was a cohort of 100 000 patients (33% female), with mean age of 63 years at the time of acute ischemic minor stroke or TIA, which is the sex distribution and mean age of the patients who were enrolled in the CHANCE trial (Clopidogrel in High‐risk patients with Acute Non‐disabling Cerebrovascular Events Trial). Patients in the two treatment arms entered the model at the Markov health state of minor or no disability and transited to other health states (ischemic stroke or intracranial hemorrhage with minor or no disability, moderate disability, severe disability, myocardial infarction, extracranial hemorrhage, and dead) in the next cycle. Death (by stroke or other causes) was the only absorbing state after which the patient was excluded from the model. Total direct medical costs and quality‐adjusted life‐years (QALYs) gained with each alternative were estimated for each health state at 90 days from onset of TIA or minor stroke and then estimated annually for the remaining 30 years. This analysis was conducted from the perspective of healthcare payers. The study protocol was approved by the ethics committee of Beijing Tiantan Hospital. All participants or their legal proxies provided written informed consent.

![Markov model showing potential transitions between health states. Locations in the model where prescribers can make a decision (squares), chance nodes that are under the control of transition probabilities (circles), and terminal nodes (triangles) are presented. Transitions to future health states leading from the ASA‐alone branch are the same as for the Clopidogrel‐ASA branch. ASA indicates aspirin; ECH, extracranial hemorrhage; ICH, intracerebral hemorrhage; M, Markov node; MI, myocardial infarction; TIA, transient ischemic attack.](jah3-3-e000912-g1){#fig01}

Input Parameters
----------------

Model input parameters were drawn from the published literature and directly from the results of the CHANCE trial (Tables [1](#tbl01){ref-type="table"} and [2](#tbl02){ref-type="table"}). The death rates and the distribution of functional outcomes of patients treated with clopidogrel‐aspirin or aspirin alone in the first 90 days were based on results from the CHANCE trial, derived directly from the trial database. Major extracranial hemorrhage risk of the two treatment arms at 90 days were estimated by excluding intracranial hemorrhage from total hemorrhage defined by GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) criteria, because extracranial hemorrhage were not explicitly defined in CHANCE trial. We assumed all patients stopped the clopidogrel‐aspirin regimen and used aspirin alone after 90 days since dual‐antiplatelet therapy is not recommended for routine secondary stroke prevention^[@b7]--[@b8]^ and aspirin alone is more commonly used than clopidogrel alone in the long‐term setting after TIA and minor stroke.^[@b9]--[@b10]^ Recurrent rates of stroke and the proportion of intracranial hemorrhage (ICH) and fatal cases in recurrent stroke in years after the first 90 days of antiplatelet therapy were estimated from the China National Stroke Registry (CNSR), a nationwide registry for patients with acute cerebrovascular events in China between September 2007 and August 2008, recruiting 21 902 consecutive patients from 132 hospitals that cover all 27 provinces and four municipalities in China, and the Nanjing Stroke Registry Program (NSRP), a total of 1432 patients with first‐ever ischemic stroke registered from July 2002.^[@b11]--[@b12]^ We further assumed an increase in stroke recurrence rates by 1.017‐fold per life‐year, according to the relative risk estimated from CNSR. Patients remaining alive after recurrent stroke events were assumed to be reallocated equally among disability categories of equal and greater disability. For example, patients with minor or no disability who had a recurrent stroke and lived were allocated equally among minor or no disability, moderate disability, and severe disability categories. Age‐specific mortality rates for nonstroke death were derived from the most recent published census of China and adjusted by the causes of death of 2010 reported in the China Health Statistics Yearbook 2012.^[@b13]--[@b14]^

###### 

Efficacy of Clopidogrel‐Aspirin Regimen for TIA and Minor Stroke

  Model Input                            Aspirin‐Alone Regimen   Clopidogrel‐Aspirin Regimen   Reference
  -------------------------------------- ----------------------- ----------------------------- -----------------------
  Proportion of patients after 90 days                                                         CHANCE trial database
  Minor or no disability (mRS 0 to 2)    0.9233                  0.9376                        
  Moderate disability (mRS 3 to 4)       0.0670                  0.0527                        
  Severe disability (mRS 5)              0.0058                  0.0058                        
  Death (mRS 6)                          0.0039                  0.0039                        
  90‐day event risks                                                                           
  Recurrent stroke                       0.1172                  0.0820                        
  Proportion of ICH                      0.0264                  0.0377                        
  Major ECH                              0.0066                  0.0108                        
  MI                                     0.0008                  0.0012                        

TIA indicates transient ischemic attack; CHANCE, Clopidogrel in High‐risk patients with Acute Non‐disabling Cerebrovascular Events Trial; mRS, modified Rankin Score; ICH, intracerebral hemorrhage; ECH, extracranial hemorrhage; MI, myocardial infarction.

###### 

Model Parameters and the Range of Values Tested in Sensitivity Analyses

  Model Input                                                          Base‐Case          Range              Reference
  -------------------------------------------------------------------- ------------------ ------------------ --------------------------------
  Cost inputs (2011 CNY)                                                                                     
  Additional cost of 90‐day clopidogrel‐aspirin regimen                1990               210 to 2388        ^[@b22]^
  One‐time hospitalization costs                                                                             
  Ischemic stroke, mRS 0 to 2                                          9866               5542 to 12519      CNSR^[@b14]^
  Ischemic stroke, mRS 3 to 5 or 6                                     13081              7383 to 17114      
  ICH, mRS 0 to 2                                                      11118              5932 to 13902      
  ICH, mRS 3 to 5 or 6                                                 14760              7665 to 19438      
  MI                                                                   16793              6545 to 29434      ^[@b14]^
  Major ECH                                                            7203               4391 to 14468      
  Annual posthospitalization costs                                                                           
  Stroke, mRS 0 to 2                                                   6920               1728 to 8639       CNSR
  Stroke, mRS 3 to 5                                                   10932              3240 to 14255      
  Utility inputs                                                                                             
  Minor or no disability (mRS 0 to 2)                                  0.75               0.70 to 0.90       ^[@b18]--[@b19],[@b23],[@b25]^
  Moderate disability (mRS 3 to 4)                                     0.39               0.10 to 0.50       
  Severe disability (mRS 5)                                            0.20               0.00 to 0.32       
  Death (mRS 6)                                                        0                  0.00 to 0.00       
  Utility of major ECH                                                 0.80               0.79 to 0.84       ^[@b18]--[@b20]^
  Utility of MI                                                        0.84               0.67 to 0.96       ^[@b18]--[@b19],[@b21]^
  Probabilities inputs                                                                                       
  Recurrent rate of stroke (per patient year)                          0.1219             0.1163 to 0.1276   CNSR^[@b12]^
  Among patients with recurrent stroke, proportion with:                                                     CNSR^[@b12]^
  ICH                                                                  0.075              0.075 to 0.146     
  Death                                                                0.1933             0.1737 to 0.2128   
  Relative risk of stroke recurrence per life‐year                     1.017              1.013 to 1.022     CNSR
  Age‐specific nonstroke death rate[\*](#tf2-1){ref-type="table-fn"}   0.0089 to 0.1654                      ^[@b13]--[@b14]^
  Rate of major ECH                                                    0.0038             0.0030 to 0.0048   ^[@b15]--[@b16]^
  Mortality rate of major ECH                                          0.06                                  ^[@b16]^
  Rate of MI                                                           0.0085             0.0060 to 0.0114   ^[@b15]--[@b16]^
  Mortality rate of fatal MI                                           0.150              0.103 to 0.246     ^[@b15],[@b17]^
  Discount rate inputs                                                                                       
  Costs                                                                0.03               0.03 to 0.08       ^[@b23]^
  Outcomes                                                             0.03               ±20%               ^[@b23]^

All costs were converted to 2011 CNY by using the medical care component of consumer price index; to convert CNY to US dollars, divide by 6.5. CNY indicates Chinese Yuan Renminbi; mRS, modified Rankin Score; CNSR, China National Stroke Registry; MI, myocardial infarction; ECH, extracranial hemorrhage; ICH, intracerebral hemorrhage.

Age‐specific nonstroke death rate for only the number of 63‐year‐olds (0.0089) and 93‐year‐olds (0.1654) is presented.

In our model, myocardial infarction and major extracranial hemorrhages were considered temporary health states unless they resulted in death. These probabilities were derived from the literature.^[@b15]--[@b17]^ For nonfatal myocardial infarction and nonfatal major extracranial hemorrhage, we further assumed that all patients entering these health states would have a short‐term disutility of only 2 weeks for nonfatal major extracranial hemorrhage and 30 days for nonfatal myocardial infarction.^[@b18]--[@b21]^

Costs
-----

All costs were total costs, including both out‐of‐pocket costs and reimbursement levels, and converted to 2011 Chinese Yuan Renminbi (CNY) by using the medical care component of consumer price index.^[@b14]^ One‐time hospitalization costs for major events and annual posthospitalization costs were based on CNSR and the China Health Statistics Yearbook 2012.^[@b14]^ Additional costs of the 90‐day clopidogrel‐aspirin regimen were based on the retail price of clopidogrel (brand) and aspirin according to Beijing Municipal Commission of Development and Reform.^[@b22]^ Indirect economic costs such as lost work productivity were not included in this analysis. All costs and utilities were discounted by 3% per year.^[@b23]^

Health States
-------------

In the model, patients could undergo transitions between four poststroke disability states based on the modified Rankin Scale (mRS): minor or no disability (mRS 0 to 2), moderate disability (mRS 3 to 4), severe disability (mRS 5), or death (mRS 6).^[@b24]^ At the end of each annual cycle, patients could remain in their current health state, transition to a lower health state due to recurrent stroke, or die due to a recurrent stroke or a nonvascular cause (see [Figure 1](#fig01){ref-type="fig"}).

Outcome Assessment
------------------

Health outcomes were measured in QALYs by multiplying years of life by utility scores derived from the literature. Utility estimates for stroke survivors were based on published utility values stratified by mRS category.^[@b18]--[@b19],[@b23],[@b25]^ Economic costs were measured as the difference of health care costs between the two treatment alternatives. The economic costs included the additional cost of the 90‐day clopidogrel‐aspirin regimen, hospitalization for stroke or TIA, myocardial infarction, extracranial hemorrhage, and posthospitalization long‐term care associated with each health state. The incremental cost‐effectiveness ratio (ICER) was calculated by dividing the cost difference by the difference in QALYs. Using the threshold of 3× GDP per capita of China in 2011 as the willingness‐to‐pay per QALY, a threshold recommended by the Commission on Macroeconomics and Health of World Health Organization,^[@b26]^ the intervention was considered cost‐effective if the ICER was \<CNY 105 000 (3× GDP per capita of China in 2011,^[@b14]^ US\$ 16 200) per QALY gained.

Sensitivity Analysis
--------------------

One‐way sensitivity analyses were performed to test the robustness of model results on all variables across plausible ranges determined a priori. Plausible ranges were obtained from the literature or by varying estimates up to 20% in each direction ([Table 2](#tbl02){ref-type="table"}). To evaluate the impact of the uncertainty in all variables simultaneously, a probabilistic sensitivity analysis was performed using Monte Carlo simulation in Ersatz v1.3 (a bootstrap add‐in for Microsoft Excel for Windows; EpiGear International Pty Ltd). Costs were varied after assuming a lognormal distribution. Probabilities and utilities were varied according to a beta distribution. The simulation was run 10 000 times to capture stability of the results. Uncertainty was represented on a scatter‐plot and cost‐effectiveness acceptability curve.

Results
=======

Base‐Case Analysis
------------------

In the base‐case scenario, for a 63‐year‐old patient with acute minor stroke or TIA, early 90‐day clopidogrel‐aspirin regimen would result in a lifetime gain of 0.037 QALY at an additional cost of CNY 1250 (US\$ 192) ([Table 3](#tbl03){ref-type="table"}).Therefore, the ICER of early 90‐day clopidogrel‐aspirin regimen would be approximately CNY 33 800 (US\$ 5200) per QALY gained. Using the threshold of CNY 105 000 (3× GDP per capita of China in 2011, US\$ 16 200) as the willingness‐to‐pay per QALY, early 90‐day clopidogrel‐aspirin regimen was more cost‐effective in the base‐case scenario.

###### 

Cost and QALYs per Capita in Base‐Case Analysis

  Strategy                      Cost (CNY)   QALYs   ICER (CNY/QALY)
  ----------------------------- ------------ ------- -----------------
  Aspirin‐alone regimen         136 850      6.461   ---
  Clopidogrel‐aspirin regimen   138 100      6.498   33 784

QALY indicates quality‐adjusted life‐year; CNY, Chinese Yuan Renminbi; ICER, incremental cost‐effectiveness ratio.

Sensitivity Analysis
--------------------

One‐way sensitivity analyses indicated that the study results were robust. The tornado diagram in [Figure 2](#fig02){ref-type="fig"} illustrates the effect of varying input parameters on the ICER. Overall, results were most sensitive to additional cost of 90‐day clopidogrel regimen and annual posthospitalization cost of disabling stroke (mRS 3 to 5). When additional cost of 90‐day clopidogrel regimen was decreased to CNY 210 (based on the generic clopidogrel price in the United States), the ICER of clopidogrel‐aspirin decreased to CNY −14 300/QALY, which represents a cost saving with improved health. When annual posthospitalization cost of disabling stroke was varied from CNY 14254.6 to CNY 3239.7, the dual‐antiplatelet therapy\'s ICER increased from CNY 25 000/QALY to CNY 53 500/QALY. The ICER was relatively insensitive to varying parameters of proportion of ICH in recurrent stroke, utility of major extracranial bleed, utility of myocardial infarction, and hospitalization cost of ICH.

![One‐way sensitivity analyses on incremental cost per quality‐adjusted life‐year (ICER) gained by 90‐day clopidogrel‐aspirin regimen. All parameters were analyzed, and only those with highest influence on ICER are displayed. The first number listed after the variable name is the base‐case value. Numbers listed in parentheses indicate the range of the variable. Dark‐shaded bars represent the lower bound of the variable range. Light‐shaded bars represent the upper bound. Solid vertical lines represent ICER of the clopidogrel‐aspirin regimen at the base‐case scenario (CNY 33 800). CNY indicates Chinese Yuan Renminbi; MI, myocardial infarction; QALYs, quality‐adjusted life‐years.](jah3-3-e000912-g2){#fig02}

Results of 10 000 iteration probabilistic sensitivity analysis are shown in [Figure 3](#fig03){ref-type="fig"}. In 10.6% of simulation runs, the clopidogrel‐aspirin therapy was less costly and more effective than aspirin‐alone therapy. Clopidogrel‐aspirin therapy was cost‐effective in 95.7% of the simulations at a willingness‐to‐pay threshold of CNY 105 000 (3× GDP per capita of China in 2011, US\$ 16 200) per QALY. It remained cost‐effective in 49.0% of the simulations at a willingness‐to‐pay threshold of CNY 35 100 (1× GDP per capita of China in 2011, US\$ 5400) per QALY. A cost‐effectiveness acceptability curve shows the probability of cost‐effectiveness of the clopidogrel‐aspirin regimen as a function of the willingness‐to‐pay threshold ([Figure 4](#fig04){ref-type="fig"}).

![Incremental cost‐effectiveness scatterplot of the result of the probabilistic sensitivity analysis. Each point represents a simulation. The dark square represents the base‐case (0.037 QALY gained at an incremental cost of CNY 1250). The solid line represents the willingness‐to‐pay threshold of CNY 105 000 per QALY. The dashed line represents CNY 35 100 per QALY. CNY indicates Chinese Yuan Renminbi; QALYs, quality‐adjusted life‐years.](jah3-3-e000912-g3){#fig03}

![Cost‐effectiveness acceptability curve results based on 10 000 Monte Carlo simulations of the model. The curve presents the probability that the clopidogrel‐aspirin regimen is cost‐effective as a function of willingness‐to‐pay threshold. The solid vertical line represents the willingness‐to‐pay threshold of CNY 105 000 per QALY. The dashed vertical line represents CNY 35 100 per QALY. CNY indicates Chinese Yuan Renminbi; QALYs, quality‐adjusted life‐years.](jah3-3-e000912-g4){#fig04}

Discussion
==========

Based largely on the results of the CHANCE trial, this cost‐effectiveness analysis demonstrates that a 90‐day clopidogrel‐aspirin regimen increases costs but improves quality of life. A patient on dual antiplatelet therapy gained an additional 0.037 QALY over a lifetime but at an additional of CNY 1250 (US\$ 192), resulting in an ICER of CNY 33 800 (US\$ 5200) per QALY. The robustness of our overall conclusion that 90‐day clopidogrel‐aspirin regimen is cost‐effective is supported by the sensitivity analysis. The lifetime gain of 0.037 QALY (0.44 quality‐adjusted months) for early 90‐day clopidogrel‐aspirin regimen of TIA and minor stroke is comparable to that of most stroke treatments. For example, the lifetime QALY gain is 0.56 for tissue plasminogen activator treatment for acute ischemic stroke in the 3‐hour time window,^[@b27]^ 0.17 for clopidogrel (ccompared with aspirin) for secondary prevention in stroke patients.^[@b15]^ The gain of QALYs associated with early 90‐day clopidogrel‐aspirin regimen of TIA and minor stroke is relatively smaller than that of other treatments mainly because, unlike other analyses did, our analysis referred to nondisabling cerebrovascular events (TIA and minor stroke) other than stroke with high severity.

Cost‐effectiveness was sensitive to the additional cost of 90‐day clopidogrel regimen and the annual posthospitalization cost of disabled stroke. When clopidogrel price was decreased to CNY 78 (US\$ 12, the generic clopidogrel price in US) for a 1‐month supply, the additional cost of 90‐day clopidogrel regimen was decreased, and dual‐antiplatelet therapy became cost saving. If the annual posthospitalization cost of disabling stroke was reduced to approximately one‐third of the base‐case level, cost saving from dual antiplatelet therapy was decreased, but the resultant ICER was still substantially lower than the willingness‐to‐pay threshold.

In current guidelines for the early management of patients with acute ischemic stroke published by both the cerebrovascular disease group of Chinese Medical Association and by the American Heart Association/American Stroke Association, clopidogrel and aspirin combination therapy is not recommended for patients with minor ischemic stroke and TIA.^[@b28]--[@b29]^ Aspirin monotherapy is the current standard of care in China. However, guidelines have not incorporated results of the CHANCE trial and patients with aspirin monotherapy still have 90‐day stroke risk of 10% to 20% after minor ischemic stroke or TIA.^[@b1]--[@b3]^ Our study suggested that clopidogrel‐aspirin combination therapy is a cost‐effective alternative over aspirin monotherapy when taken soon after a TIA or minor stroke.

Our study has limitations that should be considered when interpreting the results. First, the external generalizability of our findings may be affected as it is based on the efficacy findings from a single trial performed in China (the CHANCE trial), whose participants were restricted to Chinese patients. It is not known whether combination regimen will be shown to be similarly effective in other populations or settings. Additionally, we used a base‐case cohort based on the CHANCE trial patient characteristics (mean age was 63 years and 33% were female), with a low proportion of female TIA patients. This was different from typical TIA population from population‐based cohorts, and may result in different events rates and medical resource use.^[@b30]--[@b31]^ Second, we used most estimates from CNSR and previously published literature for our input parameters. It is possible that these estimates are inaccurate. For example, we used the costs data from CNSR and inflate the costs to 2011 Chinese Yuan Renminbi to estimate the one‐time hospitalization costs of stroke. However, hospitalization costs of stroke differed widely by location and level of hospital.^[@b14],[@b32]^ These estimates are higher than the official (mean hospital cost) figures from the Ministry of Health of China (CNY 7325.3, US\$ 1127 for ischemic stroke; CNY 11 802.1 US\$ 1816 for ICH),^[@b14]^ but comparable with those reported by the ChinaQUEST study (CNY 10 689, US\$ 1527 for ischemic stroke; CNY 13 089, US\$ 1870 for ICH, in 2006).^[@b32]^ This may have been because many of the patients in CNSR and ChinaQUEST studies were from urban locations where costs are greater. Additionally, several surveys explored poor rehabilitation and decreased adherence to secondary prevention of ischemic stroke in China after discharge,^[@b9],[@b33]--[@b36]^ which may dramatically influence the annual posthospitalization costs but would do so similarly in both groups. We estimated annual posthospital costs from data of the real world registry of CNSR. Third, in the Markov model, we assumed future transitions of health status based on events related to stroke recurrence and total nonstroke death and functional status as a result of other cause were not considered in this model. Some studies have shown that disability status also affects survival,^[@b37]--[@b38]^ and this was not included in the present analysis. Fourth, we assumed that patients remaining alive after recurrent stroke events were reallocated equally among disability categories of equal and greater disability. Finally, this analysis was conducted from the perspective of healthcare payers. If a societal perspective was taken, indirect costs such as lost work productivity should be included and it may probably influence the results of the model.^[@b5]^ These assumptions may deviate from the real world, but are unlikely to affect the overall results of our study because our findings were robust over reasonable variations in all model inputs.

Our study reflects costs and event rates in China. Results may not be generalizable to other countries. For example, the monthly cost of clopidogrel (CNY 650, US\$ 100) is substantially greater in China than in the United States, where generic clopidogrel is available for CNY 78 (US\$ 12) for a month supply while the costs of hospitalization and posthospital care are much greater in the United States. Clopidogrel will be available as a generic in China in 2017. If generic is introduced, the price will come down dramatically and will likely be cost saving.

Conclusions
===========

Early treatment with a 90‐day clopidogrel‐aspirin regimen for acute TIA or minor stroke is highly cost‐effective in China setting. Although clopidogrel is generic, Plavix is brand in China. If Plavix were generic, treatment with clopidogrel‐aspirin would have been cost saving.
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